This may favor the hepatocarcinogenic process, as observed in different models of hepatic injury ending in HCC, in which pharmacological or genetic inhibition of EGFR prevents tumor development [170,171,172]. This evidence concerns the gene EGFR and hepatocellular carcinoma.